Relief Therapeutics & NeuroX Sign Deal for MindMaze Successor Merger

• Relief Therapeutics and NeuroX have signed a definitive agreement for a business combination, creating a new AI-driven health tech company.
• The combined entity will be renamed MindMaze Therapeutics Holding SA and aims to be a global leader in neurotherapeutic solutions for neurological diseases.
• The transaction is expected to close in December 2025, pending customary conditions and approvals.
• NeuroX's digital neurotherapeutic suite is already deployed in over 250 clinics and is supported by a unique U.S. reimbursement code (CAT-3).
• The deal involves an equity valuation of CHF 100 million for Relief and CHF 1 billion for NeuroX, with Relief issuing 140 million new shares to acquire NeuroX.
• The combined company will focus on precision neurology, leveraging a proprietary neuro-data engine and advanced AI models for personalized treatment solutions.